Literature DB >> 14695200

Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation.

Disha Dadke1, Benjamin H Fryer, Erica A Golemis, Jeffrey Field.   

Abstract

Kaposi's sarcoma-associated herpes virus (KSHV) contributes to the pathogenesis of Kaposi's sarcoma and primary effusion lymphomas. KSHV encodes a G protein-coupled receptor (KSHV-GPCR) that signals constitutively and transforms NIH3T3 cells. Here, we show that KSHV-GPCR transformation requires activation of the small G protein Rac1 and its effector, the p21-activated kinase 1 (Pak1). Either transient or sustained expression of KSHV-GPCR activated both Rac1 and Pak1. Furthermore, expression of dominant-negative mutants of Rac (RacN17) or Pak1 (PakR299, Pak-PID) inhibited KSHV-GPCR-induced focus formation and growth in soft agar. We also demonstrate that signaling from Pak1 to nuclear factor-kappaB (NFkappaB) is required for cell transformation induced by KSHV-GPCR. KSHV-GPCR induced transcriptional activation by NFkappaB. This process is inhibited by the PAK-PID, whereas reciprocally, expression of constitutively active Pak1 (PakL107F) activated NFkappaB comparably to KSHV-GPCR. The Pak-PID and RacN17 inhibited the KSHV-GPCR-induced phosphorylation of inhibitor of kappaB kinase-beta and inhibitor of kappaB-alpha, implying that it is Pak1-dependent phosphorylation and subsequent destruction of the inhibitor of kappaB proteins that allows NFkappaB activation. Finally, experiments with the KSHV-GPCR inverse agonist interferon-gamma-inducible protein-10, the Galpha(i) inhibitor pertussis toxin, and an inhibitor of phosphatidylinositol 3'-kinase, wortmannin, indicate that signaling through the Galpha(i) pathway and phosphatidylinositol 3'-kinase contributes to the cell transformation and NFkappaB activation induced by the KSHV-GPCR.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695200

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor.

Authors:  Sarah J Paulsen; Mette M Rosenkilde; Jesper Eugen-Olsen; Thomas N Kledal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 3.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

Review 4.  Rho'ing in and out of cells: viral interactions with Rho GTPase signaling.

Authors:  Céline Van den Broeke; Thary Jacob; Herman W Favoreel
Journal:  Small GTPases       Date:  2014-03-24

5.  Phosphorylation and polyubiquitination of transforming growth factor beta-activated kinase 1 are necessary for activation of NF-kappaB by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Authors:  Virginie Bottero; Nagaraj Kerur; Sathish Sadagopan; Kinjan Patel; Neelam Sharma-Walia; Bala Chandran
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

6.  Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression.

Authors:  Virginie Bottero; Neelam Sharma-Walia; Nagaraj Kerur; Arun George Paul; Sathish Sadagopan; Mark Cannon; Bala Chandran
Journal:  Virology       Date:  2009-07-28       Impact factor: 3.616

Review 7.  Targeted therapy for Kaposi sarcoma.

Authors:  Ryan J Sullivan; Liron Pantanowitz; Bruce J Dezube
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

8.  In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.

Authors:  Natalia Skobeleva; Sanjay Menon; Lutz Weber; Erica A Golemis; Vladimir Khazak
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

Review 9.  An emerging role for p21-activated kinases (Paks) in viral infections.

Authors:  Celine Van den Broeke; Maria Radu; Jonathan Chernoff; Herman W Favoreel
Journal:  Trends Cell Biol       Date:  2010-01-12       Impact factor: 20.808

10.  Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.

Authors:  Luis E Arias-Romero; Olga Villamar-Cruz; Min Huang; Klaus P Hoeflich; Jonathan Chernoff
Journal:  Cancer Res       Date:  2013-04-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.